FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. An antibody or antigen-binding fragment thereof that specifically binds to mucin 1 (MUC1) is proposed. Also provided are including the specified anti-MUC1 antibody conjugate antibody-drug, bispecific antibody, T-cell, NK-cell, pharmaceutical compositions for the prevention or treatment of cancer. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, a vector and a host cell carrying said nucleic acid, and a method for producing an anti-MUC1 antibody using said vector and a host cell.
EFFECT: invention provides exceptional affinity and binding strength of an antibody or antigen-binding fragment thereof to MUC1 and can be effectively used to treat disease associated with MUC1, such as cancer.
26 cl, 45 dwg, 6 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
